Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
Expert Review of Endocrinology & Metabolism|February 15, 2011
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancerRong Hu, Samuel R Denmeade, Jun Luo
Bioconjugate Chemistry|March 16, 2006
Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approachSaurabh Aggarwal, James L Harden, Samuel R Denmeade
The Prostate|May 27, 2023
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancerLaura A Sena, Hao Wang, Samuel R Denmeade
Cell Cycle (Georgetown, Tex.)|August 19, 2017
Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancerJohn T Isaacs, W Nathaniel Brennen, Samuel R Denmeade
Luminescence : the Journal of Biological and Chemical Luminescence|September 10, 2008
Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivoSachin S Chandran, Simon A Williams, Samuel R Denmeade
Molecular Cancer Therapeutics|February 11, 2012
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategyW Nathaniel Brennen, John T Isaacs, Samuel R Denmeade
Endocrine-Related Cancer|August 27, 2013
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironmentW Nathaniel Brennen, Samuel R Denmeade, John T Isaacs
Annals of Translational Medicine|February 5, 2020
Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC)John T Isaacs, W Nathaniel Brennen, Samuel R Denmeade
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
Challenges of conducting clinical trials of natural products to combat cancerChanning J Paller, Samuel R Denmeade, Michael A Carducci
Expert Review of Clinical Pharmacology|July 15, 2021
Targeting the spectrum of immune checkpoints in prostate cancerLaura A Sena, Samuel R Denmeade, Emmanuel S Antonarakis
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
Expert Review of Endocrinology & Metabolism|February 15, 2011
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancerRong Hu, Samuel R Denmeade, Jun Luo
Bioconjugate Chemistry|March 16, 2006
Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approachSaurabh Aggarwal, James L Harden, Samuel R Denmeade
The Prostate|May 27, 2023
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancerLaura A Sena, Hao Wang, Samuel R Denmeade
Cell Cycle (Georgetown, Tex.)|August 19, 2017
Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancerJohn T Isaacs, W Nathaniel Brennen, Samuel R Denmeade
Luminescence : the Journal of Biological and Chemical Luminescence|September 10, 2008
Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivoSachin S Chandran, Simon A Williams, Samuel R Denmeade
Molecular Cancer Therapeutics|February 11, 2012
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategyW Nathaniel Brennen, John T Isaacs, Samuel R Denmeade
Endocrine-Related Cancer|August 27, 2013
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironmentW Nathaniel Brennen, Samuel R Denmeade, John T Isaacs
Annals of Translational Medicine|February 5, 2020
Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC)John T Isaacs, W Nathaniel Brennen, Samuel R Denmeade
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
Challenges of conducting clinical trials of natural products to combat cancerChanning J Paller, Samuel R Denmeade, Michael A Carducci
Expert Review of Clinical Pharmacology|July 15, 2021
Targeting the spectrum of immune checkpoints in prostate cancerLaura A Sena, Samuel R Denmeade, Emmanuel S Antonarakis
Pageof 16